Search

Your search keyword '"Decker, Thomas"' showing total 1,506 results

Search Constraints

Start Over You searched for: Author "Decker, Thomas" Remove constraint Author: "Decker, Thomas"
1,506 results on '"Decker, Thomas"'

Search Results

1. Explanatory Model Monitoring to Understand the Effects of Feature Shifts on Performance

2. Provably Better Explanations with Optimized Aggregation of Feature Attributions

3. Does Your Model Think Like an Engineer? Explainable AI for Bearing Fault Detection with Deep Learning

4. Explaining Deep Neural Networks for Bearing Fault Detection with Vibration Concepts

5. Towards Scenario-based Safety Validation for Autonomous Trains with Deep Generative Models

6. The Thousand Faces of Explainable AI Along the Machine Learning Life Cycle: Industrial Reality and Current State of Research

8. JAK-STAT signaling maintains homeostasis in T cells and macrophages

13. Third International Consensus Conference on lesions of uncertain malignant potential in the breast (B3 lesions)

15. The Oncology Biomarker Discovery framework reveals cetuximab and bevacizumab response patterns in metastatic colorectal cancer

16. The INFINITY study protocol: a retrospective cohort study on decision making and clinical impact of biomarker-driven precision oncology in routine clinical practice

17. PRECYCLE: multicenter, randomized phase IV intergroup trial to evaluate the impact of eHealth-based patient-reported outcome (PRO) assessment on quality of life in patients with hormone receptor positive, HER2 negative locally advanced or metastatic breast cancer treated with palbociclib and an aromatase inhibitor or palbociclib and fulvestrant

18. Efficacy, safety, and prognosis prediction in patients treated with ribociclib in combination with letrozole: Final results of phase 3b RIBECCA study in hormone receptor positive, human epidermal growth factor receptor-2 negative, locally advanced or metastatic breast cancer

21. Standard diametric versus volumetric early tumor shrinkage as a predictor of survival in metastatic colorectal cancer: subgroup findings of the randomized, open-label phase III trial FIRE-3 / AIO KRK-0306

22. Favorable impact of therapy management by an interactive eHealth system on severe adverse events in patients with hormone receptor-positive, HER2-negative locally advanced or metastatic breast cancer treated by palbociclib and endocrine therapy

23. Anti-hormonal maintenance treatment with the CDK4/6 inhibitor ribociclib after 1st line chemotherapy in hormone receptor positive / HER2 negative metastatic breast cancer: A phase II trial (AMICA)

28. Efficacy of FOLFIRI plus cetuximab vs FOLFIRI plus bevacizumab in 1st-line treatment of older patients with RAS wild-type metastatic colorectal cancer: an analysis of the randomised trial FIRE-3

30. Consensus molecular subtypes (CMS) as prognostic and predictive biomarkers of RAS wild-type (WT) metastatic colorectal cancer (mCRC): Pooled analysis of the randomized trials FIRE-1, FIRE-3, XELAVIRI, and PanaMa.

31. Correction to: Second International Consensus Conference on lesions of uncertain malignant potential in the breast (B3 lesions).

32. Second International Consensus Conference on lesions of uncertain malignant potential in the breast (B3 lesions).

33. First-line fluoropyrimidine plus bevacizumab followed by irinotecan-escalation versus initial fluoropyrimidine, irinotecan and bevacizumab in patients with metastatic colorectal cancer – Final survival and per-protocol analysis of the randomised XELAVIRI trial (AIO KRK 0110)

35. Best Management Practices for Trapping Furbearers in the United States

36. Infrared properties of micromachined vanadium oxide thin films

37. Efficacy and safety of everolimus plus exemestane in patients with hormone receptor‐positive, HER‐2‐negative advanced breast cancer: Results from the open‐label, multicentre, non‐interventional BRAWO study.

40. Impact of Primary Tumor Sidedness on Prognosis and Anti-EGFR Antibody Efficacy in BRAF-Mutant Metastatic Colorectal Cancer: A Pooled Analysis of AIO Studies FIRE-1, CIOX, FIRE-3, XELAVIRI, and VOLFI

43. FOLFIRI plus cetuximab or bevacizumab for advanced colorectal cancer: final survival and per-protocol analysis of FIRE-3, a randomised clinical trial

45. First International Consensus Conference on lesions of uncertain malignant potential in the breast (B3 lesions).

46. An efficient quantum algorithm for finding hidden parabolic subgroups in the general linear group

48. Polynomial time quantum algorithms for certain bivariate hidden polynomial problems

49. The impact of mammalian target of rapamycin inhibition on bone health in postmenopausal women with hormone receptor-positive advanced breast cancer receiving everolimus plus exemestane in the phase IIIb 4EVER trial

50. Hidden Symmetry Subgroup Problems

Catalog

Books, media, physical & digital resources